RU94042656A - Method of treatment of liver primary cancer and set for treatment of liver primary cancer - Google Patents

Method of treatment of liver primary cancer and set for treatment of liver primary cancer

Info

Publication number
RU94042656A
RU94042656A RU94042656/14A RU94042656A RU94042656A RU 94042656 A RU94042656 A RU 94042656A RU 94042656/14 A RU94042656/14 A RU 94042656/14A RU 94042656 A RU94042656 A RU 94042656A RU 94042656 A RU94042656 A RU 94042656A
Authority
RU
Russia
Prior art keywords
doxorubicin
sterile
treatment
volume
fetoprotein
Prior art date
Application number
RU94042656/14A
Other languages
Russian (ru)
Other versions
RU2065307C1 (en
Inventor
А.В. Тихонов
В.М. Щербаков
В.И. Володарский
Original Assignee
А.В. Тихонов
В.М. Щербаков
В.И. Володарский
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by А.В. Тихонов, В.М. Щербаков, В.И. Володарский filed Critical А.В. Тихонов
Priority to RU9494042656A priority Critical patent/RU2065307C1/en
Priority to AU19641/95A priority patent/AU1964195A/en
Priority to PCT/RU1995/000030 priority patent/WO1996018410A1/en
Application granted granted Critical
Publication of RU2065307C1 publication Critical patent/RU2065307C1/en
Publication of RU94042656A publication Critical patent/RU94042656A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

FIELD: medicine, oncology. SUBSTANCE: method involves administration of doxorubicin dissolved in lipiodol ultrafluid in hepatic artery. Doxorubicin preparation is doxorubicin-estrone dissolved in 96% ethyl alcohol at 70-76 C at dose 20-60 mg in 10-15 ml lipiodol ultrafluid. Preliminary (before 20 min) alpha-fetoprotein is administrated in hepatic artery at dose 2-10 mg in 12-15 ml physiological solution, and repeated treatment is carried out in 3-4 weeks. The set contains sterile doxorubicin-estrone at amount 20-60 mg in vials (volume is 15 ml), sterile lipiodol ultrafluid in two ampoules (volume of each is 10 ml) and additionally - sterile lyophilized human alpha-fetoprotein at amount 1-10 mg in vials (volume is 10 ml), sterile physiological solution (15 ml in ampoule) and 96% ethyl alcohol (5 ml in ampoule). EFFECT: improved method of cancer treatment. 2 cl

Claims (1)

Изобретение относится к области медицины, в частности, к онкологии и может найти применение при химиотерапии онкологических пациентов, страдающих первичным раком печени. Способ лечения первичного рака печени, включающий введение в печеночную артерию препарата доксорубицина, растворенного в липиодол ультрафлуиде, отличающийся тем, что в качестве препарата доксорубицина используют доксорубицинэстрон, растворенный в 96%-ном этиловом спирте при 70-76oС в дозе 20-60 мг на 10-15 мл липиодол ультрафлуида, при этом предварительно за 20 мин в печеночную артерию вводят альфа-фетопротеин в дозе 2-10 мг в 12-15 мл физраствора, причем повторное лечение проводят через 3-4 недели. Набор для лечения первичного рака печени, содержащий препарат доксорубицина и липиодол ультрафлуид, отличающийся тем, что в качестве препарата доксорубицин он содержит стерильный доксорубицин-эстрон в количестве 20-60 мг в пузырьках вместимостью 15 мл, стерильный липиодол ультрафлуид в двух ампулах по 10 мл, и дополнительно - стерильный лиофилизированный препарат альфа-фетопротеина человека в количестве 1-10 мг в пузырьках вместимостью 10 мл, стерильный физиологический раствор объемом 15 мл в ампуле и 96%-ный этиловый спирт объемом 5 мл в ампуле.The invention relates to medicine, in particular to oncology, and may find application in chemotherapy of cancer patients suffering from primary liver cancer. A method of treating primary liver cancer, comprising administering to the hepatic artery a preparation of doxorubicin dissolved in lipiodol ultrafluid, characterized in that doxorubicinestron dissolved in 96% ethanol at 70-76 ° C. in a dose of 20-60 mg is used as a doxorubicin preparation 10-15 ml of lipiodol ultrafluid, in which case alpha-fetoprotein in a dose of 2-10 mg in 12-15 ml of saline is preliminarily injected into the hepatic artery for 20 minutes, and repeated treatment is carried out after 3-4 weeks. Primary liver cancer treatment kit containing doxorubicin and lipiodol ultrafluid, characterized in that as doxorubicin, it contains sterile doxorubicin-estrone in an amount of 20-60 mg in 15 ml vials, sterile lipiodol ultrafluid in two 10 ml ampoules, and additionally, a sterile lyophilized preparation of human alpha-fetoprotein in an amount of 1-10 mg in vials with a capacity of 10 ml, sterile physiological saline solution with a volume of 15 ml in an ampoule and 96% ethyl alcohol with a volume of 5 ml in an ampoule.
RU9494042656A 1994-12-13 1994-12-13 Method of primary liver cancer treatment and kit for primary liver cancer treatment RU2065307C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
RU9494042656A RU2065307C1 (en) 1994-12-13 1994-12-13 Method of primary liver cancer treatment and kit for primary liver cancer treatment
AU19641/95A AU1964195A (en) 1994-12-13 1995-02-22 Agent for treating primary liver cancer and a method of treating primary liver cancer
PCT/RU1995/000030 WO1996018410A1 (en) 1994-12-13 1995-02-22 Agent for treating primary liver cancer and a method of treating primary liver cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU9494042656A RU2065307C1 (en) 1994-12-13 1994-12-13 Method of primary liver cancer treatment and kit for primary liver cancer treatment

Publications (2)

Publication Number Publication Date
RU2065307C1 RU2065307C1 (en) 1996-08-20
RU94042656A true RU94042656A (en) 1997-06-10

Family

ID=20162826

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9494042656A RU2065307C1 (en) 1994-12-13 1994-12-13 Method of primary liver cancer treatment and kit for primary liver cancer treatment

Country Status (3)

Country Link
AU (1) AU1964195A (en)
RU (1) RU2065307C1 (en)
WO (1) WO1996018410A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2179452C1 (en) 2000-06-22 2002-02-20 Пак Владимир Николаевич Method to treat malignant neoplasms and combined preparation of antitumor action to perform the method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888172A (en) * 1982-09-23 1989-12-19 Alfaceu Corporation Pharmaceutical for treating tumors and methods for making it
IE60059B1 (en) * 1985-04-19 1994-05-18 Oncogene Science Inc Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
FI883337A (en) * 1987-07-16 1989-01-17 Bristol Myers Co ICKE-VATTENLOESNINGAR AV DOXORUBICINHYDROKLORIN.
EP0407451A1 (en) * 1988-03-11 1991-01-16 CERCEK, Boris General cancer-associated scm-recognition factor, preparation and method of use
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
IL96499A0 (en) * 1990-11-28 1991-08-16 Eytan Barnea Anticancer protein-like extract
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1

Also Published As

Publication number Publication date
AU1964195A (en) 1996-07-03
RU2065307C1 (en) 1996-08-20
WO1996018410A1 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
US4999375A (en) Psoralen reagent compositions for extracorporeal treatment of blood
SEKI et al. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats
RU95101385A (en) Products containing g-csf and tnf-binding protein
US6720011B1 (en) Injectable composition for cancer treatment
RU2003122061A (en) ANTIATEROSCLEROTIC COMPOSITION CONTAINING CAROTINOIDS AND METHOD FOR INHIBITING OXIDATION OF LOW DENSITY Lipoprotein (LDL)
JPH01503146A (en) Methods of treating body tissue and administering medicines to body tissue
RU2335539C2 (en) Pharmaceutical preparation and method of malignant tumours treatment at the person using arginine deprivation
JPS6366128A (en) C-reactive protein useful for remedy of animal and human cancer
WO2002007708A1 (en) Lyophilized powder of lentinan and the process of preparation thereof
JPS61155324A (en) Anticancer drug and remedy
RU94042656A (en) Method of treatment of liver primary cancer and set for treatment of liver primary cancer
FI105075B (en) Use of combination injection product
Janzing et al. Intrapleural quinacrine instillation for recurrent pneumothorax or persistent air leak
Lauret et al. Vegetating iodides after an intravenous pyelogram
JP3022915B2 (en) Cancer metastasis inhibitor
US3885030A (en) Medicine comprising lysine by-products
RU2157218C2 (en) Method of immunotherapy of chronic inflammatory diseases
Liau et al. Study about Wound Healing, Evolution of Cancer and War on Cancer
RU2359664C1 (en) Pharmaceutical injection composition on basis of tilorone for treatment of purulent-destructive processes with signs of immune insufficiency
RU2045961C1 (en) Method of experimental coronarography
RU2203667C2 (en) Method for treating lymphoproliferative diseases
RU2123342C1 (en) Method of treatment of patients with lung cancer
JPH01216938A (en) Use of tumor necrosis factor and lymphotoxin to production of drug
FR2007399A1 (en) Organotherapeutic solution for administering large drug - doses
RU2133610C1 (en) Method for treating the cases of psoriatic erythrodermia